Premium
Model‐Based Meta‐Analysis: An Important Tool for Making Quantitative Decisions During Drug Development
Author(s) -
Mould D R
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.122
Subject(s) - drug development , meta analysis , clinical trial , computer science , drug , risk analysis (engineering) , medicine , intensive care medicine , pharmacology
Modeling during drug development is routinely used to integrate subject‐level information, evaluate response, and inform clinical trials. Model‐based meta‐analysis (MBMA) combines aggregate safety and efficacy results from many trials. Because MBMA is based on results from large numbers of subjects, it increases the power to precisely detect small but clinically significant effects, providing a basis for quantitative drug development decisions and reducing time and cost. This Commentary describes an overview of MBMA and its application during drug development. Clinical Pharmacology & Therapeutics (2012); 92 3, 283–286. doi: 10.1038/clpt.2012.122